Forum Discussion

arpie's avatar
arpie
Member
12 hours ago

Giredestrant Reduces Recurrence Risk More Than Tamoxifen, Aromatase Inhibitors - lidERA Trial

Is/was anyone on the 'lidERA' Trial? Apparently there is evidence that Giredestrant may Reduce Recurrence Risk up to 30% More Than Tamoxifen, Aromatase Inhibitors. https://www.breastcancer.org/r...
ai
clinical-trial
Mez_BCNA's avatar
Mez_BCNA
Community Manager
5 hours ago

Thanks for sharing arpie​ - really interesting and encouraging research. It’s great to see consistent findings across studies in other countries, as that broader evidence can really help influence future treatment guidelines.